Trial Profile

An Open-label, Phase II Study of ADX-2191 in Subjects With Retinitis Pigmentosa

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 12 Aug 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Methotrexate (Primary)
Indications Retinitis pigmentosa
Focus Adverse reactions; Proof of concept
Sponsors Aldeyra Therapeutics

Most Recent Events

24 Jul 2025 According to an Aldeyra Therapeutics media release, company announced that the European Medicines Agency (EMA) has granted Orphan Designation for ADX-2191 (methotrexate intravitreal injection) for the treatment of inherited retinal dystrophies.
29 Jun 2023 Status changed from active, no longer recruiting to completed.
29 Jun 2023 According to an Aldeyra Therapeutics media release, Ramiro S. Maldonado is the principal investigator for this trial.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com